Clinical trials likely slowed by Covid-19

Coronavirus will have a “big or extremely big” impact on clinical trial sites, a new survey shows — hampering their ability to recruit patients for new studies, or keep them enrolled in ongoing trials. 

“There’s plenty of early evidence that a serious shutdown in clinical trials is in the works,” one analyst wrote in an investor note, adding that this would have  “widespread ramifications” for biopharma, “either from readout delays or from more ‘missing data’ in ongoing trials.” 

Read more.